u/Imaginary_Weight6488

I keep thinking about 3D Systems and about an asset that’s not on a balance sheet.

We talks about printers, materials, patents, quarterly revenue, margins, debt, and the stock chart.

But…. WHAT ABOUT DATA?

3D Systems has been in additive manufacturing since the beginning. Since the 1980s. That means they haven’t just been selling machines, they’ve been watching the entire industry learn how to print.

Not just clean, successful prints either.

The failures too.

And honestly, the failures are just as valuable.

Think about what gets learned OVER DECADES of real-world manufacturing:

Which laser settings work.
Which scan speeds fail.
Which materials warp.
Which geometries crack.
Which support structures save a build.
Which chamber conditions matter.
Which post-processing steps change final performance.
Which inspection results actually correlate with part quality.

Now multiply that across aerospace, healthcare, dental, jewelry, industrial parts, motorsports, defense, and bioprinting.

That is not GENERIC internet SCRAPED data.

That is hard-earned manufacturing knowledge.

This is where the AI angle gets interesting. Everyone says AI is only as good as the data it’s trained on. So who has one of the deepest additive manufacturing data histories on the planet?

??????????????????????????

A usual startup cannot just download forty years of print outcomes, machine behavior, materials testing, failed builds, successful builds, process qualifications, CT scans, porosity measurements, dimensional inspections, and customer application knowledge.

🔥🔥🔥🔥That kind of dataset is built slowly, painfully, over decades.🔥🔥🔥

Now imagine what a domain-specific manufacturing AI could do with the right portion of that knowledge.

It could help predict failed builds before they happen, recommend better print orientation, help choose materials, suggest parameter changes for difficult geometries.

It could optimize supports, estimate mechanical performance before the part is printed, shorten process development from months to weeks, give engineers access to decades of lessons in seconds.

That is a very different kind of AI than a chatbot.

That is manufacturing intelligence.

And to be clear, I’m not saying 3D Systems can just throw every customer file into an AI model. There are contracts, privacy issues, medical regulations, defense restrictions, export controls, and customer IP concerns. All of that matters.

But even after those limits, the company likely still has a huge amount of proprietary internal R&D data, process knowledge, materials data, machine data, and application experience that it does have the right to use.

DATA is one of the most underappreciated pieces of the story.

The market is valuing DDD like an old 3D printing hardware company 😂😂😂😂😂😂😂😂😂😂😂😂😂😂😂

But the future of additive manufacturing is not only be about who has the best printer. It’s about who has the best manufacturing AI

Because once AI starts moving deeper into design-to-production workflows, the company with the deepest real-world additive dataset will have a serious moat.

The most valuable thing is not the machine. It’s everything the machine has learned.

https://preview.redd.it/a5yo92fg7a8h1.png?width=1556&format=png&auto=webp&s=77f1f37a164e585c2fd79eb321d0e2cacc2e33ef

This paper looks small on the surface but becomes much more interesting once you understand what it is really saying.

The study is about COAPTIUM CONNECT, a first-of-its-kind sutureless peripheral nerve repair system developed by TISSIUM and enabled in part by 3D Systems’ 3D bioprinting  manufacturing capabilities.

This is about replacing one of surgery’s most delicate manual techniques with a bioabsorbable, light-activated, 3D-enabled repair system designed to reduce trauma, improve consistency, and make nerve repair more controlled.

https://preview.redd.it/rktzxhur7a8h1.png?width=2514&format=png&auto=webp&s=e89c4e5a8879700e1ab99b502877fd5fa0e32258

The framing of the paper is simple: traditional nerve repair is difficult. For decades, microsurgical sutures have been the gold standard for repairing severed nerves. But sutures are not perfect. They require high skill, high precision, magnification, and a very steady hand. They can also place stress directly on the nerve ends, create local trauma, increase scarring risk, and introduce variability depending on surgeon technique.

In other words, the old method works, but it is highly dependent on human execution.

That is the first important investor takeaway.

Whenever a medical device can reduce dependence on ultra-fine manual technique and make a procedure more reproducible, it has the potential to become valuable. Not because surgeons are not skilled, but because every operating room benefits when a complex procedure becomes more standardized.

The next section of the paper moves into the concept: a sutureless approach.

https://preview.redd.it/v7nimttw7a8h1.png?width=2846&format=png&auto=webp&s=6f78e82b4c0f3eaad303c127b237c7d8e41245ae

COAPTIUM CONNECT is built around a bioabsorbable coaptation chamber and a light-activated polymer. The chamber helps align and protect the nerve ends. The polymer is delivered into the chamber and activated with light to secure the repair. Instead of stitching through delicate nerve tissue, the system creates a protected environment where the nerve ends are held in alignment while healing begins.

https://preview.redd.it/upk85r3c7a8h1.png?width=1510&format=png&auto=webp&s=65039f2ded72bdec475b755e895cf87c767ea34a

The device is not trying to “force” the nerve together with tiny stitches. It is trying to create a controlled biological workspace around the repair.

This was a prospective, single-arm clinical study in patients with digital nerve injuries. Twelve patients were enrolled, and ten completed the full one-year follow-up. The results section is the part that should catch attention. Among the patients who completed the study, 100% achieved “Good” or “Excellent” static two-point discrimination scores at both 6 months and 12 months. 

The paper also reported that no patients had pain at 12 months, no device-related complications were observed, ultrasound confirmed intact repairs, and no neuromas were seen. A neuroma is painful, disruptive nerve tissue growth that can occur after nerve injury or repair. If a repair approach can reduce trauma and protect the repair site, avoiding neuroma formation is clinically important.

The study also reported that all patients recovered full flexion and extension of the affected digit, and median return-to-work time was under six weeks.

https://preview.redd.it/v2b5ar3c7a8h1.png?width=1522&format=png&auto=webp&s=b4cefcffc3c0f755640cc794176838dcda126ed8

Again, this is early data and a small sample. But the pattern is attractive: sensory recovery, no pain at 12 months, no device-related complications, intact repair, no neuroma, and functional digit movement.

For investors, the important concept: reproducibility.

Medicine does not scale only through brilliant surgeons. It scales through systems that help brilliant surgeons produce consistent results across more patients, more hospitals, and more real-world conditions.

https://preview.redd.it/mymkwm3c7a8h1.png?width=2048&format=png&auto=webp&s=6e5ef00b92cb6438195b8583c997a090ad6d315c

3D Systems is not the brand on the front of the device. TISSIUM is. But 3D Systems enables the solution through its regenerative medicine and 3D bioprinting technologies. The device includes a 3D-printed bioabsorbable chamber, and the broader collaboration reflects exactly where additive manufacturing becomes more than “printing parts.” It moves 3D printing from industrial production into biological architecture.

The same philosophical shift keeps repeating across the 3D Systems story:

In aerospace, additive allows impossible metal geometries.
In dental, additive allows digital workflows and recurring material usage.
In craniomaxillofacial surgery, additive allows patient-specific planning and guides.
In regenerative medicine, additive begins to structure the environment where tissue can heal, connect, or eventually be manufactured.

It is a real FDA-authorized device category, with early human clinical data, tied to a commercial U.S. product launch.

https://preview.redd.it/q59c3q3c7a8h1.png?width=2048&format=png&auto=webp&s=edb89177c877ef74bf3fe9c845a139cf0412e645

For a moderately informed investor, the point is not that COAPTIUM alone transforms 3D Systems overnight. It will not. The point is that it validates a deeper capability stack: materials science, bioabsorbable implants, light-activated polymers, precision 3D-printed structures, and regulated medical workflows.

Is 3D Systems just selling printers, or is it an enabling layer for advanced medical manufacturing?

COAPTIUM CONNECT suggests the second answer may be more interesting.

And if that is true, then this paper is not just a clinical update.

It is a glimpse of where additive manufacturing starts helping the body repair itself.

https://preview.redd.it/os5w3iff8a8h1.png?width=3850&format=png&auto=webp&s=327b8b08a5e2c210e055a2db159e4d05cfd1708c

According to CEO Jeffrey Graves, 3D Systems is adding approximately 80,000 square feet of new production space adjacent to its existing facility, with a targeted opening around late July to early August.

What stood out was the reason for the expansion. Graves explained that the existing operation has historically focused on healthcare manufacturing, but demand for industrial production has continued to increase. The company reached a point where it needed an entirely separate facility dedicated to industrial manufacturing.

His words:

“There’s more demand than we can handle in our current facility.”

That is a very different message from the narrative many investors have become accustomed to hearing.

The new facility is expected to support areas such as:

Aerospace
Drones
Advanced industrial applications
High-performance materials

When you combine this with the Air Force large-format metal printer project, the company’s growing aerospace and defense focus, and broader industry trends toward domestic manufacturing, the expansion looks less like a capacity scaling event.

The market is currently focused on financing, dilution, and short-term price movements. Meanwhile, DDD is preparing to open an entirely new manufacturing facility because demand has exceeded existing capacity.

What are everyone’s thoughts on the significance of this expansion?